テキサスにおける胃癌の臨床試験
テキサス内の拠点で、胃癌に関する60件の研究が参加者を募集しています。
テキサス内の都市
- Houston42件の研究
- Dallas19件の研究
- San Antonio19件の研究
- Austin10件の研究
- Irving7件の研究
- Fort Worth5件の研究
- Tyler4件の研究
- League City3件の研究
公式研究テキスト（英語）
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- NEXT Oncology, Austin
- UT Southwestern, Dallas
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06172478A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Texas Oncology - Amarillo Cancer Center, Amarillo
- Texas Oncology-Austin Central, Austin
- Texas Oncology, Beaumont
- 他4件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07221149AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Research Site, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06219941Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
- Baylor Scott & White Health, Dallas
- MD Anderson Cancer Center, Houston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07700979Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
- NEXT Houston, Galveston
- NEXT Oncology - PARENT, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07360314A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- NEXT Dallas, Irving
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07578571IKS014 in Advanced Solid Tumors That Express HER2
- START Dallas - Fort Worth, Fort Worth
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05872295Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
- US Oncology Investigational Products Center (IPC), Irving
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07392892Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06047379Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Houston
被験者募集中第2相
18歳〜130歳 · 全性別 · 2026/09/23更新 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- MD Anderson, Houston
- NEXT Dallas, Irving
- NEXT Oncology San Antonio, San Antonio
- 他1件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Texas Oncology - DFW (Sammons CC), Dallas
- MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07114601A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213791A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07705334Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- Texas Oncology (Balcones) - SCRI, Austin
- MD Anderson Cancer Center, Houston
- START South Texas Accelerated Research Therapeutics, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT05267626Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Start - Dfw, Fort Worth
- Oncology Consultants, Houston
- START - San Antonio, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NEXT Oncology - Austin, Austin
- Mary Crowley Cancer Research, Dallas
- MD Anderson Cancer Center - University of Texas, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06253871Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Dallas
- Research Site, Dallas
- Research Site, Houston
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07431281Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
- Mary Crowley Cancer Research, Dallas
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06750185Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
- UT MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06364410A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics (START), LLC, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/02更新 · NCT07070232A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- NEXT Austin, Austin
- NEXT San Antonio, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/27更新 · NCT07227168A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Research Site, Houston
- Research Site, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT07115043A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- NEXT Dallas, Irving
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/13更新 · NCT07066657A Study of MGC026 in Participants With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- University of Texas Health Science Center at Houston, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06242470A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The University of Texas, MD Anderson Cancer Center, Houston
- UT Health Mays Cancer Center, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- UT Southwestern Medical Center, Dallas
- Texas Oncology, P.A. - Tyler, Tyler
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06731478A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
- Clinical Trial Site, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/06更新 · NCT07749586IDOV-Immune for Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- South Texas Accelerated Research Therapeutics, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/05更新 · NCT06910657A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Texas Oncology, Dallas
- Oncology Consultants, Houston
- Texas Oncology, Tyler
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/29更新 · NCT03526835Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- The University of Texas Health Science Center at Tyler, Tyler
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/29更新 · NCT04198766Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #129, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/23更新 · NCT06974110A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- 他8件
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT05208762A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Dallas, Irving
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/22更新 · NCT06131840A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
- Texas Oncology - Central South, Austin
- START San Antonio, LLC., San Antonio
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/15更新 · NCT06657144A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
- Texas Oncology - DFW, Dallas
- MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/10更新 · NCT06695845A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
- 他5件
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/06更新 · NCT04389632ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。